CN Patent

CN108503627A — 用作egfr抑制剂的2,4-二取代苯-1,5-二胺衍生物及其应用

Assigned to Tetranov Pharmacy Stock Inc · Expires 2018-09-07 · 8y expired

What this patent protects

本发明公开了一种式Ⅰ所示的2,4‑二取代苯‑1,5‑二胺衍生物、其药学上可接受的盐、立体异构体、溶剂化物或前药，其中的各符号如权利要求中所定义。本发明的2,4‑二取代苯‑1,5‑二胺衍生物可以抑制一种或多种EGFR的激活或抗性突变，可用于EGFR敏感型突变癌症的治疗，还适用于目前EGFR‑TKI治疗中产生继发性耐药的病例，是一种理想的由EGFR突变导致的疾病的治疗药物。

USPTO Abstract

本发明公开了一种式Ⅰ所示的2,4‑二取代苯‑1,5‑二胺衍生物、其药学上可接受的盐、立体异构体、溶剂化物或前药，其中的各符号如权利要求中所定义。本发明的2,4‑二取代苯‑1,5‑二胺衍生物可以抑制一种或多种EGFR的激活或抗性突变，可用于EGFR敏感型突变癌症的治疗，还适用于目前EGFR‑TKI治疗中产生继发性耐药的病例，是一种理想的由EGFR突变导致的疾病的治疗药物。

Drugs covered by this patent

mobocertinib-succinate (MOBOCERTINIB SUCCINATE)

Patent Metadata

Patent number: CN108503627A
Jurisdiction: CN
Classification: —
Expires: 2018-09-07
Drug substance claim: No
Drug product claim: No
Assignee: Tetranov Pharmacy Stock Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.